Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program-Reference-Cited by-同舟云学术

Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program

Published:2024-01-02 Issue:1 Volume:331 Page:72
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Socal Mariana P.¹,Wang Yuchen¹,Plummer Elizabeth²,Anderson Gerard F.¹,Bai Ge³

Affiliation:

1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

2. Neeley School of Business, Texas Christian University, Fort Worth

3. Johns Hopkins Carey Business School, Washington, DC

Abstract

This study compares Medicare and patient spending for dual over-the-counter and prescription drugs with their over-the-counter cash prices.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2813273/jama_socal_2023_ld_230080_1703181677.62609.pdf

Reference5 articles.

1. Comparative approaches to drug pricing.;Kang;Annu Rev Public Health,2020

2. Comparison of spending on common generic drugs by Medicare vs Costco Members.;Trish;JAMA Intern Med,2021

3. Potential Medicare Part D savings on generic drugs from the Mark Cuban Cost Plus Drug Co.;Lalani;Ann Intern Med,2022

4. Chapter 6: Part D Drugs and formulary requirements. In Medicare Part D Prescription Drug Benefit Manual. Centers for Medicare and Medicaid Services (CMS); 2016. Accessed May 17, 2023. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf

5. Nonprescription Drug Product with an Additional Condition for Nonprescription Use. US Food and Drug Administration; 2022. Accessed July 17, 2023. https://www.federalregister.gov/documents/2022/06/28/2022-13309/nonprescription-drug-product-with-an-additional-condition-for-nonprescription-use